Phase I clinical trial using selective cyclooxygenase-2 (Cox-2) inhibitor celecoxib with concurrent thoracic irradiation in patients with poor prognosis non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Liao, Z
Komaki, R
Milas, L
Chen, Y
Chang, JY
Jeter, M
Guerrero, T
Craig, SW
Blumenschien, G
Smith, CM
Cox, JD
机构：
[1] Univ Houston, MD Anderson Canc Ctr, Houston, TX USA
[2] Canc Hosp, Tongji Sch Med, Wuhan, Hu Bei, Peoples R China
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2004年 / 60卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
37
引用
收藏
页码：S151 / S151
页数：1
相关论文
共 50 条
  • [1] Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, enhances the response to carboplatin and weekly paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Nishiyama, O
    Taniguchi, H
    Kondoh, Y
    Kimura, T
    Kato, K
    Tanikawa, Y
    Aoyama, M
    Suzuki, R
    Shimokata, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 698S - 698S
  • [2] A phase II study of carboplatin (C) and weekly paclitaxel (P) with a selective cyclooxygenase-2 (COX-2) inhibitor, meloxicam, in advanced non-small cell lung cancer (NSCLC)
    Suzuki, R.
    Yamamoto, M.
    Saka, H.
    Taniguchi, H.
    Shindo, J.
    Tanikawa, Y.
    Nomura, S.
    Oishi, T.
    Hasegawa, Y.
    Shimokata, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
    Khuri, FR
    Wu, H
    Lee, JJ
    Kemp, BL
    Lotan, R
    Lippman, SM
    Feng, L
    Hong, WK
    Xu, XC
    CLINICAL CANCER RESEARCH, 2001, 7 (04) : 861 - 867
  • [4] Cyclooxygenase-2 (COX-2) inhibition with meloxicam in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC).
    Takahashi, T
    Ueda, S
    Ebisawa, M
    Asai, G
    Yamamoto, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 686S - 686S
  • [5] Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel
    Csiki, I
    Morrow, JD
    Sandler, A
    Shyr, Y
    Oates, J
    Williams, MK
    Dang, T
    Carbone, DP
    Johnson, DH
    CLINICAL CANCER RESEARCH, 2005, 11 (18) : 6634 - 6640
  • [6] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Gadgeel, Shirish M.
    Ruckdeschel, John C.
    Heath, Elisabeth I.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Wozniak, Antoinette
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
  • [7] Expression and prognostic significance of cyclooxygenase-2 (COX-2) in non-small cell lung carcinoma
    Goncharuk, VN
    Kren, L
    Anwar, S
    Sheehan, CE
    Xiong, JJ
    Ross, JS
    MODERN PATHOLOGY, 2002, 15 (01) : 320A - 320A
  • [8] Expression and prognostic significance of cyclooxygenase-2 (COX-2) in non-small cell lung carcinoma
    Goncharuk, VN
    Kren, L
    Anwar, S
    Sheehan, CE
    Xiong, JJ
    Ross, JS
    LABORATORY INVESTIGATION, 2002, 82 (01) : 320A - 320A
  • [9] Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer
    Gridelli, C
    Maione, P
    Airoma, G
    Rossi, A
    CURRENT MEDICINAL CHEMISTRY, 2002, 9 (21) : 1851 - 1858
  • [10] Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer
    Gadgeel, Shirish M.
    Wozniak, Antoinette
    Ruckdeschel, John C.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Chaplen, Ruth A.
    Kraut, Michael J.
    Kalemkerian, Gregory P.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) : 1293 - 1300
12345